Sonoma Pharmaceuticals reported QQ2 2025 results reflecting a modest improvement in top-line performance alongside ongoing profitability challenges. Revenue for the quarter stood at $3.58 million, up 31.1% year over year and 5.5% quarter over quarter, driven by continued demand for its stabilized HOCl portfolio across wound care, dermatology, eye care, and animal health. However, operating losses persisted (EBITDA of -$0.82 million and net income of -$0.61 million), with an implied cost base that continues to outpace revenue growth. The company maintained a solid balance sheet with ample liquidity, ending the period with cash and cash equivalents of $4.08 million and net debt of -$3.83 million, signaling substantial runway for near-term initiatives. Free cash flow remained positive at $0.33 million, underscoring the potential for cash-accretive actions as revenue scales. Management commentary is not available in the supplied transcript dataset, limiting direct quotes from the earnings call. Nevertheless, the quarterly trajectory suggests a company transitioning from early-stage revenue expansion to stabilization, with a focus on margin optimization and portfolio expansion to sustain longer-term value creation.